Pulmokine Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $20M

Pulmokine General Information

Description

Developer of biopharmaceutical therapies designed to treat pulmonary arterial hypertension (PAH) and related disorders. The company's pulmonary disease and kinase inhibitor technology treats crucial lung conditions, enabling patients suffering from lung diseases to access pulmonary drugs.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 7 University Place
  • Room B127
  • Rensselaer, NY 12144
  • United States
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Corporate Office
  • 7 University Place
  • Room B127
  • Rensselaer, NY 12144
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pulmokine Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 26-Nov-2024 $20M Completed Generating Revenue
6. Secondary Transaction - Private Completed Generating Revenue
5. Grant 01-Jan-2017 Completed Generating Revenue
4. Grant 01-Jan-2016 Completed Generating Revenue
3. Seed Round 04-Mar-2015 Completed Generating Revenue
2. Debt - General 01-Oct-2014 Completed Generating Revenue
1. Grant 01-Jan-2014 $1.5M Completed Generating Revenue
To view Pulmokine’s complete valuation and funding history, request access »

Pulmokine Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of biopharmaceutical therapies designed to treat pulmonary arterial hypertension (PAH) and related disorders.
Biotechnology
Rensselaer, NY

Bridgewater, NJ
 

Austin, TX
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pulmokine Competitors (29)

One of Pulmokine’s 29 competitors is Insmed, a Formerly VC-backed company based in Bridgewater, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Insmed Formerly VC-backed Bridgewater, NJ
Lung Therapeutics Formerly VC-backed Austin, TX
Cortalix Venture Capital-Backed Groningen, Netherlands
Artizan Biosciences Venture Capital-Backed New Haven, CT
hVIVO Formerly VC-backed London, United Kingdom
You’re viewing 5 of 29 competitors. Get the full list »

Pulmokine Patents

Pulmokine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210038510-A1 Formulations of kinase inhibitors and prostanoids Inactive 08-Feb-2018
US-20180117039-A1 Combination therapy for treating pulmonary hypertension Active 27-Oct-2016
EP-3532063-A1 Combination therapy for treating pulmonary hypertension Pending 27-Oct-2016
US-20200261448-A1 Combination therapy for treating pulmonary hypertension Active 27-Oct-2016
CA-3041679-A1 Combination therapy for treating pulmonary hypertension Pending 27-Oct-2016 A61K31/497
To view Pulmokine’s complete patent history, request access »

Pulmokine Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Broadview Ventures Venture Capital Minority
National Heart, Lung, and Blood Institute Government
National Institute Of Allergy and Infectious Diseases Government
To view Pulmokine’s complete investors history, request access »

Pulmokine FAQs

  • When was Pulmokine founded?

    Pulmokine was founded in 2007.

  • Where is Pulmokine headquartered?

    Pulmokine is headquartered in Rensselaer, NY.

  • What industry is Pulmokine in?

    Pulmokine’s primary industry is Biotechnology.

  • Is Pulmokine a private or public company?

    Pulmokine is a Private company.

  • What is the current valuation of Pulmokine?

    The current valuation of Pulmokine is .

  • What is Pulmokine’s current revenue?

    The current revenue for Pulmokine is .

  • How much funding has Pulmokine raised over time?

    Pulmokine has raised $1M.

  • Who are Pulmokine’s investors?

    Broadview Ventures, National Heart, Lung, and Blood Institute, and National Institute Of Allergy and Infectious Diseases have invested in Pulmokine.

  • Who are Pulmokine’s competitors?

    Insmed, Lung Therapeutics, Cortalix, Artizan Biosciences, and hVIVO are some of the 29 competitors of Pulmokine.

  • When was Pulmokine acquired?

    Pulmokine was acquired on 26-Nov-2024.

  • Who acquired Pulmokine?

    Pulmokine was acquired by Xoma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »